FDA Rejects Summit Therapeutics' China-Developed Lung Cancer Drug
The FDA declined to approve ivonescimab, a lung cancer treatment invented in China that Summit Therapeutics sought to bring to the U.S. market.
The U.S. Food and Drug Administration has rejected ivonescimab, a lung cancer drug developed in China that had drawn significant attention from investors and oncology researchers watching for potential breakthroughs in the crowded non-small cell lung cancer treatment landscape.
Summit Therapeutics, a Florida-based biopharmaceutical company, had been working to bring the drug to American patients after licensing it from a Chinese developer. The rejection marks a setback for the company's core pipeline and raises fresh questions about the regulatory pathway for drugs originally developed outside the United States.
Read more Musk Eyes Tesla-SpaceX Merger as Firms Already Share Deep Ties →
Ivonescimab had been closely watched in part because it represents a wave of oncology compounds originating from Chinese biotechnology firms that are now seeking approval in Western markets. Its fate at the FDA was seen as a bellwether for how U.S. regulators would treat such drugs amid broader geopolitical scrutiny of pharmaceutical supply chains and foreign drug development.
The FDA's decision does not necessarily foreclose all future prospects for the drug, as companies in similar situations have pursued additional clinical trials or submitted new data packages in response to agency feedback. Summit Therapeutics had not immediately disclosed the specific grounds on which the agency based its rejection.
The outcome underscores the high regulatory bar that drug developers must clear before reaching U.S. patients and the particular challenges facing companies seeking to commercialize foreign-originated therapeutics in the American market. Continue reading at NYT > Business.